Heron Therapeutics Inc. (以下简称"Heron Therapeutics")近日披露了2025年第四季度及全年的初步未经审计净营收数据。根据初步统计，该公司在2025年第四季度实现了显著的收入增长，其中术后镇痛药物Zynrelef®成为该季度业绩增长的最大贡献者。这一积极表现凸显了Zynrelef®在市场中的强劲需求及其对公司整体营收的拉动作用。
同时公布的2025年全年初步净营收数据也反映出公司业务的整体稳健态势。尽管面临市场竞争和行业挑战，Heron Therapeutics通过核心产品的商业化推进，保持了可持续的发展势头。公司表示，完整的经审计财务报告将在后续按规定时间发布，届时将提供更详细的财务指标和业务进展分析。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.